Abstract
The treatment of melanoma has seen significant progress over the past 12 years. Its basis is immunotherapy using check-point inhibitors.
Unfortunately, despite the long-term therapeutic response that can be achieved, many patients experience lower rates of therapeutic responses and failure with this form of treatment even after an initial good treatment response. These treatment complications are the subject of many studies that document individual mechanisms of primary and secondary resistance to melanoma immunotherapy.
The study comprehensively describes contemporary knowledge about particular resistance mechanisms to melanoma treatment.